Here’s a round up of the reaction to news that a vaccine may very soon be available for Covid-19, followed by a more analytical piece by the BMJ.
- Who will get the vaccine first and when can you have it?
- Have we finally got a coronavirus vaccine?
- ‘Milestone’ vaccine offers 90% Covid protection
- UK government response to Pfizer/BioNTech’s publication of efficacy data of their COVID-19 vaccine Pfizer/BioNTech published positive efficacy results from Phase 3 studies of their potential COVID-19 vaccine.
A vaccine candidate developed by Pfizer and BioNTech may be more than 90% effective in preventing covid-19 in participants without prior infection, the first interim analysis of the phase III trial shows.
The research team evaluated the results after 94 cases of covid-19 had been confirmed. The study began in July and has so far enrolled nearly 44 000 participants, just under 39 000 of whom have received a second dose of the mRNA vaccine candidate (as of 8 November).
The team’s announcement said, “The case split between vaccinated individuals and those who received the placebo indicates a vaccine efficacy rate above 90%, at seven days after the second dose. This means that protection is achieved 28 days after the initiation of the vaccination, which consists of a two-dose schedule.” However, the results, which are the first from any phase III trial of a covid-19 vaccine, have been shared only by press release and have not yet been published or peer reviewed.
Experts have welcomed the news but emphasised the importance of seeing the full results and understanding many of the details not yet made public, including the participants’ demographic details and the severity of the cases reported in the trial. Read Full Report